Premium
Elevated Lin28B expression is correlated with lymph node metastasis in oral squamous cell carcinomas
Author(s) -
Lin WeiTung,
Shieh TzongMing,
Yang LiChiu,
Wang TungYuan,
Chou MingYung,
Yu ChengChia
Publication year - 2015
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12314
Subject(s) - arecoline , gene knockdown , cancer research , downregulation and upregulation , metastasis , biomarker , gene silencing , pathology , cell growth , biology , cell , cancer , medicine , cell culture , gene , receptor , biochemistry , muscarinic acetylcholine receptor , genetics
Background Lymph node ( LN ) metastasis is the most common cause of oral squamous cell carcinoma ( OSCC )‐related death. Searching the detailed molecular mechanisms involved LN metastasis in OSCC is still an open question. Methods Paired tissue samples from tumor (T) and adjacent non‐cancerous matched tissues ( NCMT ) parts, as well as LN metastatic lesions in patient with OSCC tissues were subjected to quantitative real‐time PCR analysis for the expression levels of Lin28B. Arecoline, a major areca nut alkaloid, was to explore whether expression of Lin28B could be changed dose dependent in oral epithelial cells. Control and Lin28B‐knockdown arecoline‐stimulated oral epithelial cells were subjected to migration/invasion/anchorage‐independent growth assay. Results Compared with NCMT samples from the same OSCC patient, the expression of Lin28B was increased in all of the tumor samples. A similar upregulation of Lin28B was also observed in LN metastatic when compared with local tumors. Arecoline treatment dose dependently induced Lin28B expression in SG and FaDu cells. Lentiviral‐mediated silencing Lin28B expression significantly attenuated arecoline‐induced oncogenicity including proliferation, migration, invasiveness, and anchorage‐independent growth in SG and FaDu cells. Conclusions Lin28B may be a useful biomarker and novel molecular target for LN metastasis OSCC patients' treatment.